Media OutReach Newswire

2024-12-20 15:45

Agilis Robotics completes world's first robot-assisted bladder tumour resection in clinical trial

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - Agilis Robotics has announced the successful completion of the world's first robot-assisted en-bloc resection of a bladder tumour (ERBT) using its self-developed, fully flexible endoscopic surgical robotic system. The procedure was performed by a renowned urology team at a leading hospital in Hong Kong as part of an ongoing clinical trial.

image-1.jpeg

The groundbreaking achievement represents a significant milestone in the application of robotic technology for minimally invasive treatment of bladder cancer, offering a promising new surgical option for patients worldwide. Robot-assisted ERBT can enable surgeons to remove bladder tumours in a single piece with greater precision, improving cancer staging accuracy and lowering recurrence rates compared to traditional techniques.

Transforming Bladder Cancer Treatment with Robotic Innovation

The gold standard for early-stage bladder cancer treatment is transurethral resection of bladder tumours (TURBT), which involves removing tumours in a piece-by-piece fashion. However, this traditional piecemeal approach can result in floating tumour cells and incomplete tumour resection, leading to higher recurrence rates and poor cancer staging.

Agilis Robotics' endoscopic surgical robotic system addresses these challenges with a pair of fully flexible robotic arms that allow surgeons to precisely resect tumours in one piece (i.e. en-bloc). This approach reduces the risk of tumour cell reimplantation, improves specimen integrity for pathological analysis, and significantly decreases the likelihood of cancer recurrence.

Precision, Usability, and Accessibility Redefined

Bladder tumour resections are often complicated by the location of tumours, such as the bladder dome and anterior wall, which are highly challenging to resect completely. The robotic system developed by Agilis Robotics can provide urologists with dexterous and delicate control over the tumour resection process, enabling safer and more precise tumour resection, even in challenging cases.

Agilis Robotics completes world's first robot-assisted bladder tumour resection in clinical trial

Designed with intuitive controls and advanced robotic capabilities, the system can be adopted easily by both experienced surgeons and trainees. By reducing the learning curve for performing ERBT, it has the potential to make this advanced technique more widely available, improving outcomes for patients around the world.

Pioneering Natural Orifice Surgical Robotics

Founded in 2021, the Hong Kong-based Agilis Robotics specializes in developing innovative surgical robots designed to operate through natural orifices such as the urethra, mouth, or anus, eliminating the need for external incisions to treat early-stage tumours.

The company's robotic system has reached the critical stages of regulatory applications to the FDA and NMPA. If approved, it is poised to become the first commercially available robotic system for transurethral bladder tumour resection.

With its unique technological advantages and significant market potential, the company has secured more than US$17 million in funding, positioning itself as a leader in natural orifice surgical robotics.

Expanding the Boundaries of Minimally Invasive Surgery

The successful demonstration of robot-assisted ERBT not only provides a breakthrough treatment option for bladder cancer but also opens the door to broader applications of minimally invasive robotic surgery through natural orifices, including procedures for the colon and upper gastrointestinal tract.

Agilis Robotics is committed to advancing medical technology, driving innovation, and delivering impactful solutions that benefit patients worldwide.
Hashtag: #agilisrobotics

發佈者對本公告的內容承擔全部責任

source: Agilis Robotics

樂本健【活力健康 迎新年】維柏健B+C維他命 激抵買低至$99► 了解詳情

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
4
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
5
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
6
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
7
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
8
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
9
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
10
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
11
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
12
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
13
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
14
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
15
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
16
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
17
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
18
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
19
回顧展望-息息相關 | 銀行股明年看好滙控,重組有利減低支出
20
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
21
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
22
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
23
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
24
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
25
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
26
回顧展望-A股自強 | 憧憬國策利好,機構對明年股市走勢樂觀
27
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
28
藍圖2.0 | 旅遊發展藍圖2.0提四大策略,推特色項目智慧旅遊並開拓客源
29
港股 | 蕭猷華:恒指春節前可挑戰21500點
30
電動車 | 寧德時代:擬發行H股香港上市
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運飾物

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老